Munich – November 18, 2024 – athagoras group is proud to announce the acquisition of CSO Pharma Consulting, a strategic move that will bolster our capabilities in providing comprehensive consulting services for the pharmaceutical industry. This acquisition aligns with our vision to create a leading European service group for the pharmaceutical and biotech industries. It enables CSO Pharma Consulting, a specialized service provider in the fields of pharmacovigilance, medical affairs, quality management and GDP (Good Distribution Practice) consulting to extend its offerings while leveraging athagoras’ market presence and expertise. In addition to exploring new growth opportunities, CSO remains committed to organic development, focusing on internal innovation and expanding its core services.
“We are excited to embark on this next phase of the CSO journey with athagoras,” said Dr. Silke Ostermann, CEO of CSO Pharma Consulting. “We believe this partnership will lead to long-term innovation and strengthen our ability to contribute to patients’ health all over the world.” For CSO clients, the partnership with athagoras provides more comprehensive solutions and increased service efficiency. Clients will continue to enjoy seamless support with further opportunities. CSO remains dedicated to its trusted reputation and reliable internal structure, ensuring continuity for both clients and employees.
“We are thrilled to welcome CSO into the athagoras family,” said Roman Rittweger, CEO of athagoras group. “Their deep industry knowledge and commitment to excellence and innovation perfectly complement our strategic goals. Together, we will deliver unparalleled value to our clients.”
The acquisition is a testament to athagoras group’s commitment to purposeful growth. As we continue to expand our footprint, we remain dedicated to delivering high-quality, tech-enabled services that meet the dynamic needs of our clients.
